The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Clinical stage biotech company Hexima (HXL) has decided not to proceed with developing its lead product candidate, pezadeftide, to treat onychomycosis
  • The decision comes after weak clinical data was reported for the drug’s phase two clinical trial which aimed to treat onychomycosis, a fungal nail infection
  • HXL won’t make any further significant investments into the product and has started wrapping up operational activities
  • Shares have fallen 46.2 per cent on the back of this news to trade at 1.4 cents each at midday AEST

Hexima’s (HXL) shares plummeted as the company plans to wind down activities for its leading product candidate, pezadeftide.

The decision came after weak clinical data was reported for the drug’s phase two clinical trial.

The trial saw 103 patients participate in the study, which aimed to treat onychomycosis, a fungal nail infection that causes discolouration, thickening, and separation from the nail bed.

No patients saw a complete cure and only a handful recorded improvements.

The company said it “does not believe the data supports the company’s goal of developing a safe, more effective and convenient topical therapy with a shorter course of treatment.”

HXL will make no further significant investments into the product and has initiated the process of wrapping up operational activities.

It has begun exploring strategic options to secure value for its intellectual property and residual cash resources.

At the end of June, the company had $4 million in cash and expects to receive $5.6 million from the government’s R&D Tax Incentive scheme.

Shares dropped 46.2 per cent to 1.4 cents each at midday trade AEST.

HXL by the numbers
More From The Market Online
The Market Online Video

Market Close: Green lights up on ASX for Easter hunt go

The ASX200 closed the day in record territory - nearly a per cent up with every…

Week 13 Wrap: Easter bunny delivers new all time high for ASX200

Another week, another all time high. The ASX200 clocked 7,901pts on Thursday for the first time…

Market shrugs as Fisher & Paykel announces mass recall

Fisher & Paykel has initiated a voluntary limited recall of batches of Airvo 1 and my…
The Market Online Video

Market Update: ASX glows red hot with another hit record

The ASX200 is trading up, hitting a new high of 7901 point and eclipsing the last…